Table 2.

Unadjusted Mean, Standard Deviation and Interquartile Range of Proportion of Days Covered (PDC) by a Statin and Adherence Status of Users over Each Interval, Overall and by Cancer Site

					Adherence Status
PDC					PDC ≥0.80		PDC 0.20–0.79		PDC<0.20
All cancers	n	Mean	SD	IQR	n	%	n	%	n	%
Year–2	10,177	0.8	0.28	0.73–1.00	7,089	69.7	2,478	24.4	610	6
Year –1	10,177	0.8	0.29	0.72–1.00	7,073	69.5	2,361	23.2	743	7.3
Year +1	10,177	0.79	0.29	0.72–1.00	7,060	69.4	2,280	22.4	837	8.2
Year +2	10,177	0.79	0.3	0.73–1.00	7,135	70.1	2,155	21.2	887	8.7
Breast cancer
Year –2	3,153	0.79	0.29	0.68–1.00	2,115	67.1	825	26.2	213	6.8
Year –1	3,153	0.78	0.29	0.68–1.00	2,114	67.1	789	25	250	7.9
Year +1	3,153	0.77	0.31	0.68–0.99	2,131	67.6	726	23	296	9.4
Year +2	3,153	0.78	0.31	0.69–1.00	2,128	67.5	724	23	301	9.6
Colorectal cancer
Year –2	1,762	0.81	0.27	0.74–1.00	1,247	70.8	414	23.5	101	5.7
Year –1	1,762	0.8	0.28	0.73–1.00	1,228	69.7	417	23.7	117	6.6
Year +1	1,762	0.76	0.31	0.68–0.97	1,146	65	445	25.3	171	9.7
Year +2	1,762	0.78	0.31	0.71–1.00	1,202	68.2	378	21.5	182	10.3
Prostate cancer
Year –2	5,262	0.81	0.27	0.74–1.00	3,727	70.8	1,239	23.6	296	5.6
Year –1	5,262	0.81	0.28	0.74–1.00	3,731	70.9	1,155	22	376	7.2
Year +1	5,262	0.81	0.28	0.76–1.00	3,783	71.9	1,109	21.1	370	7
Year +2	5,262	0.81	0.29	0.76–1.00	3,805	72.3	1,053	20	404	7.7

Notes: Estimates are presented for each study interval: Year –2 is the 12–24 months prior to cancer diagnosis; Year –1 is the 0–11 months prior to cancer diagnosis; Year +1 is the 0–11 months following cancer diagnosis; Year +2 is the 12–24 months following cancer diagnosis. Adherent levels were defined as: adherent (PDC≥0.80); partial-adherent (PDC=0.20–0.79) and non-adherent (PDC<0.20). The proportion of patients across adherence levels, in any year, may not add to 100% due to rounding. Abbreviations: n=number of participants evaluated at each study interval; PDC=proportion of days covered; SD=standard deviation; IQR=interquartile range.